Pharming Group N.V.
PHAR
$8.51
-$0.07-0.82%
NASDAQ
| 12/31/2024 | 06/30/2024 | 12/31/2023 | 09/30/2023 | ||
|---|---|---|---|---|---|
| Revenue | 92.67M | 74.09M | 81.22M | 66.66M | |
| Total Other Revenue | -- | -- | -- | -- | |
| Total Revenue | 92.67M | 74.09M | 81.22M | 66.66M | |
| Cost of Revenue | 12.21M | 7.98M | 7.12M | 8.30M | |
| Gross Profit | 80.46M | 66.11M | 74.10M | 58.37M | |
| SG&A Expenses | 46.56M | 48.55M | 57.28M | 36.01M | |
| Depreciation & Amortization | -- | -- | -- | -- | |
| Other Operating Expenses | -143.00K | -912.00K | 20.74M | -304.00K | |
| Total Operating Expenses | 80.94M | 77.21M | 96.51M | 64.75M | |
| Operating Income | 11.73M | -3.12M | -15.29M | 1.91M | |
| Income Before Tax | 6.68M | -60.00K | -2.03M | 3.31M | |
| Income Tax Expenses | 3.82M | 1.16M | 1.09M | -157.00K | |
| Earnings from Continuing Operations | 2.86M | -1.22M | -3.12M | 3.46M | |
| Earnings from Discontinued Operations | -- | -- | -- | -- | |
| Extraordinary Item & Accounting Change | -- | -- | -- | -- | |
| Minority Interest in Earnings | -- | -- | -- | -- | |
| Net Income | 2.86M | -1.22M | -3.12M | 3.46M | |
| EBIT | 11.73M | -3.12M | -15.29M | 1.91M | |
| EBITDA | 19.43M | -1.17M | -7.74M | 4.81M | |
| EPS Basic | 0.00 | 0.00 | 0.00 | 0.01 | |
| Normalized Basic EPS | 0.01 | 0.00 | -0.02 | -- | |
| EPS Diluted | 0.00 | 0.00 | 0.00 | 0.01 | |
| Normalized Diluted EPS | 0.01 | 0.00 | -0.02 | -- | |
| Average Basic Shares Outstanding | 740.00M | 688.98M | 675.00M | 692.80M | |
| Average Diluted Shares Outstanding | 740.00M | 688.98M | 675.00M | 692.80M | |
| Dividend Per Share | -- | -- | -- | -- | |
| Payout Ratio | -- | -- | -- | -- | |